Division of Hematology/Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA.
Semin Oncol. 2017 Dec;44(6):381-384. doi: 10.1053/j.seminoncol.2018.01.002. Epub 2018 Jan 12.
Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world. Front line treatment has shifted but ultimately has landed on a bortezomib-based combination therapy. Carfilzomib is a next-generation proteasome inhibitor shown to improve both progression-free and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd). Given the favorable response rates seen in phase II trials treating newly diagnosed myeloma, this combination is listed as a viable option for upfront treatment. This systematic review compares pharmacologic properties, clinical efficacy, and toxicities of carfilzomib- and bortezomib-based regimens.
多发性骨髓瘤是一种血液系统恶性肿瘤，目前无法治愈，在全球范围内有很大影响。一线治疗已经发生转变，但最终还是落在了硼替佐米为基础的联合治疗上。卡非佐米是一种新一代蛋白酶体抑制剂，与来那度胺和地塞米松（KRd）联合使用，显示可改善复发和难治性多发性骨髓瘤的无进展生存期和总生存期。鉴于 II 期临床试验中治疗新诊断骨髓瘤的高缓解率，该联合方案被列为一种可行的一线治疗选择。本系统评价比较了卡非佐米和硼替佐米为基础方案的药理学特性、临床疗效和毒性。
